Cholangiocarcinoma (CC) is a primary tumour originating from the bile duct epithelium and is classified as either intrahepatic or extrahepatic ([@bib9]; [@bib1]). As a result of the different embryological origins of extrahepatic and intrahepatic bile ducts, there may be the phenotypic diversity between extrahepatic and intrahepatic CC ([@bib9]). Extrahepatic CC (EHCC) is a highly malignant neoplasm, and the 5-year survival rate for patients who undergo surgical resection is reported to be only 20--40% ([@bib5]; [@bib37]). Extrahepatic CC is a relatively uncommon disease with a reported incidence of 1--2 cases per 100 000 per year ([@bib37]). The therapeutic gold standard for EHCC is complete resection of the tumour; however, local and distant recurrences occur in many patients after surgery ([@bib5]; [@bib2]; [@bib37]). Therefore, for such biologically aggressive EHCC, adjuvant therapy is often needed after surgical resection. For this reason, it is necessary to identify factors that can accurately predict outcomes in patients with EHCC.

Epithelial--mesenchymal transition (EMT) was first recognised as a central differentiation process in early embryogenic morphogenesis, and is characterised by loss of cell-to-cell junctions, specifically loss of epithelial phenotypes, and increased mobility due to cells gaining mesenchymal phenotypes ([@bib33]). The hallmark of EMT is downregulation of E-cadherin, an essential transmembrane protein for stable adherence junctions, and upregulation of mesenchymal molecules such as vimentin, fibronectin and N-cadherin ([@bib33]).

Epithelial--mesenchymal transition is also regulated by several transcription factors, such as Snail, Slug, Twist, Zeb1 and Zeb2 ([@bib35]; [@bib28]; [@bib14]; [@bib39]; [@bib36]; [@bib26]; [@bib10]; [@bib17]; [@bib24]; [@bib31]; [@bib4]; [@bib19]). The functions of these factors are regulated by complex signalling networks present in the tumour microenvironment, such as transforming growth factor *β*, notch and Wnt pathways ([@bib33]; [@bib26]; [@bib19]).

It has recently become clear that EMT has an important role in tumour progression and metastasis ([@bib33]). In the gastrointestinal tract, many studies have shown that EMT is implicated in the progression and metastasis of cancers such as oesophageal ([@bib36]; [@bib31]), gastric ([@bib18]; [@bib24]; [@bib4]; [@bib25]), colorectal ([@bib28]; [@bib17]) and pancreatic cancers ([@bib14]; [@bib19]). Many EMT-related proteins including transcription factors have been investigated, and some of them have been shown to correlate with poor prognosis in some carcinomas ([@bib33]). Moreover, 'cadherin switch\', one aspect of EMT showing a loss of E-cadherin expression and a gain of N-cadherin expression, has a profound effect on tumour invasion/metastasis and is associated with unfavourable outcomes in several types of cancer ([@bib11]; [@bib40]; [@bib16]; [@bib2]). Loss of E-cadherin expression and gain of N-cadherin expression is reminiscent of the cadherin switching that is seen during normal embryonic development and probably underpins many of the phenotypic changes in cancers. To our knowledge, only a few reported case series of EHCC have investigated a clinicopathological significance of EMT and cadherin switch in relation to tumour progression ([@bib26]; [@bib2]; [@bib8]). However, these studies were limited by the small numbers of cases and EMT-related proteins investigated, the prognostic significance of EMT and cadherin switch in EHCC has not yet been examined in detail.

The aim of this study was to investigate the clinicopathological significance of the expression of EMT-related proteins and cadherin switch in a large series of patients who underwent resection of EHCC.

Materials and methods
=====================

Cell lines
----------

First of all, we need to validate antibodies used in this study, because many of the EMT-related proteins especially transcription factors have not been fully studied in actual surgically resected EHCC. The pancreatic adenocarcinoma cell lines Panc-1 and AsPc-1, the lung adenocarcinoma cell lines H1299 and H1650, and the breast carcinoma cell lines MDA-MB231, MCF7 and T47D were used for antibody validation ([@bib14]; [@bib32]; [@bib10]; [@bib6]). Panc-1, H1299 and MDA-MB231 were cultured in D-MEM (Gibco BRL, Grand Island, NY, USA), and AsPc-1, H1650 and T47D were grown in RPMI-1640 (Sigma-Aldrich Japan, Tokyo, Japan), both of which were supplemented with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin. MCF7 was cultured in D-MEM supplemented with 10% FBS, 1% penicillin/streptomycin and 1% non-essential amino acids. All cell lines were maintained in a humidified incubator with 5% CO~2~ in air at 37 °C.

Reverse transcription-polymerase chain reaction
-----------------------------------------------

Total RNAs from the cell lines were extracted using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and cDNA was synthesised with the Transcript First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN, USA) in accordance with the manufacturer\'s protocols. The expression of EMT transcription factors was examined by reverse transcription polymerase chain reaction (RT--PCR) using the following primers ([@bib14]; [@bib20]): Snail (557 bp) (forward) 5′-CAGACCCACTCAGATGTCAA-3′, (reverse) 5′-CATAGTTAGTCACACCTCGT-3′ Slug (182 bp) (forward) 5′-TGCGATGCCCAGTCTAGAAA-3′, (reverse) 5′-TTCTCCCCCGTGTGAGTTC-3′ Twist (196 bp) (forward) 5′-GTCCGCAGTCTTACGAGGAG-3′, (reverse) 5′-TGGAGGACCTGGTAGAGGAA-3′ Zeb1 (195 bp) (forward) 5′-CCTGTCCATATTGTGATAGAGGC-3′, (reverse) 5′-ACCCAGACTGCGTCACATGT-3′ Zeb2 (190 bp) (forward) 5′-AGGGACAGATCAGCACCAAA-3′, (reverse) 5′-GTGCGAACTGTAGGAACCAG-3′ GAPDH (150 bp) (forward) 5′-ATCAAGTGGGGCGATGCTG-3′, (reverse) 5′-ACCCATGACGAACATGGGG-3′.

GAPDH cDNA was amplified as a control. The PCR conditions were: initial denaturing at 94 °C for 5 min, followed by 30 cycles of denaturing at 94 °C for 30 s, annealing at 55 °C for 30 s and extension at 72 °C for 60 s. All PCR products were visualised by electrophoresis and ethidium bromide staining in 2% agarose gels.

Samples from patients
---------------------

Surgical specimens of resected EHCC obtained between January 1995 and November 2006 at the Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, were used in this study. A total of 117 specimens obtained from 92 males and 25 females (median age 71 years, range 44--87 years) were examined using the tissue microarray method. The median follow-up period was 26 months (range 0--151 months), and 89 patients (76.1%) died during follow-up. None of the patients received chemotherapy preoperatively. The tumour stage was classified according to the 7th TMN classification of the Union for International Cancer Control ([@bib30]). Extrahepatic CC was classified as a perihilar (*n*=74) or distal (*n*=43) on the basis of the location of the tumour epicentre or predominance of the main tumour ([@bib5]; [@bib7]). Macroscopically, the tumours were classified into three broad categories: papillary (*n*=18), nodular (*n*=79) and infiltrating (*n*=20). The latter two categories were grouped together as non-papillary tumours because the papillary form has specifically been associated with favourable survival outcomes ([@bib15]). Superficial spread was defined as extension of noninvasive carcinoma (carcinoma *in situ*) by \>20 mm from the main tumour ([@bib21]). All informed consent processes for this study were conducted in accordance with the guidelines of the Hokkaido University Institutional Review Board.

Tissue microarray
-----------------

Archival slides for all the cases were reviewed to select two representative areas (both the invasive front and bulk of tumour) and one representative area of non-neoplastic bile duct as an internal control. Tissue microarray blocks were then constructed using a manual tissue microarrayer (JF-4; Sakura Finetek Japan, Tokyo, Japan) with a 2.0-mm diameter needle. The finalised array blocks were sliced into 4-*μ*m-thick sections and mounted on glass slides. To check the histopathological diagnosis and adequacy of tissue sampling, a section from each microarray was stained with haematoxylin and eosin and examined by an experienced pathologist (TM).

Immunohistochemical evaluation
------------------------------

Tissue sections were deparaffinised in xylene and rehydrated through a graded ethanol series. Heat-induced antigen retrieval was carried out in high-pH antigen retrieval buffer (Dako Cytomation, Glostrup, Denmark). Endogenous peroxidase was blocked by incubation in 3% H~2~O~2~ for 5 min. Details of the primary antibodies used are listed in [Table 1](#tbl1){ref-type="table"}. These sections were visualised by the HRP-labelled polymer method (Dako EnVision FLEX system) and an automated immunostaining system (Dako Autostainer Link). Immunostained sections were counterstained with haematoxylin, dehydrated in ethanol and cleared in xylene. Double immunostaining for N-cadherin and E-cadherin was performed using the HRP/DAB and ALP/Permanent red detection systems, respectively. After immunostaining for N-cadherin as described above, the sections were heat treated to strip the first step antibody in citrate-based buffer pH 6.0 (Dako Cytomation). The sections were immunostained for E-cadherin, and then visualised using the ALP-labelled LSAB method (Ventana iVIEW universal kit, Basel, Switzerland). Immunostained sections were counterstained with haematoxylin.

In this study, we evaluated immunohistochemical staining in terms of both staining intensity and proportion of stained tumour cells in the TMA cores. We initially evaluated the staining intensities of tumour cells, based on the staining of the control normal bile duct epithelium. The staining of epithelial markers E-cadherin and CK19 were considered positive (high expression), if the staining intensity was equivalent to that in normal epithelium. The staining of mesenchymal and transcription factor markers were considered positive (high expression), if weak to strong positive staining was seen compared with normal epithelium. The proportions of tumour cells with recognised staining alteration compared with normal epithelium were quantified as a percentage of the total number of tumour cells for an each TMA core. The staining results of these 12 markers were finally evaluated based on the mean proportion of two EHCC cores in each case. As for the evaluation of podoplanin, stromal expression of podoplanin was defined as positive when over than 30% of stromal fibroblastic cells were stained, as previously reported ([@bib29]). Ki67-positive cells were evaluated after identifying the areas where the highest number of the nuclear-positive cells were detected or 'hot spots\'. In this study, we used *α*-smooth muscle actin (*α*-SMA) as markers for both mesenchymal (i.e., EMT-related) and cancer-associated fibroblasts (CAFs). As for the immunohistochemical evaluation of *α*-SMA as CAFs\' marker, the staining in the fibroblasts within tumour stroma was qualitatively classified into four groups (grade 0, +1, +2 and +3), as previously reported ([@bib3]). For statistical analysis, the grades 0 and +1 were categorised as negative expression and grades +2 and +3 as positive expression.

Two researchers (TN and TM), who were blinded to the patients\' clinical information, independently examined and scored each case. Differences in interpretation were resolved by consensus agreements of them.

Statistical analysis
--------------------

To determine a suitable cutoff point for the proportion of tumour cells with recognised staining alteration and dichotomising the level of immunohistochemical staining into either high or low expression groups, we used a receiver operating characteristic (ROC) curve according to the previous report ([@bib34]) with modifications. The values of the proportions of tumour cells with recognised staining alteration as a continuous variable and survival (alive or dead at the median follow-up time) as a binary variable were subjected to ROC analysis.

Statistical analysis of the immunohistochemical staining was performed using the *χ*^2^ test, Fisher\'s exact test and Mann--Whitney *U*-test. Overall patient survival was calculated from the date of surgery to the date of the last follow-up or patient death. Univariate survival analysis was performed according to the Kaplan--Meier method, and survival was compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards regression model. The level for significance was *P\<*0.05 and the confidence interval (CI) was determined at the 95% level. Statistical analysis was performed using the JMP 10.0 software package (SAS Institute, Inc., Cary, NC, USA) for Windows.

Results
=======

Antibody validation for immunohistochemistry of EMT transcription factors
-------------------------------------------------------------------------

We validated the antibodies against EMT transcription factors and optimised their staining conditions in formalin-fixed, paraffin-embedded (FFPE) materials because these antibodies are not generally used for routine histological diagnoses and less well characterised. Positive and negative control FFPE cell blocks were prepared on the basis of the results obtained by RT--PCR ([Supplementary Data 1a](#sup1){ref-type="supplementary-material"}). Representative immunohistochemical staining patterns for EMT transcription factors are shown in [Supplementary Data 1b](#sup1){ref-type="supplementary-material"}. These validation data are also incorporated in [Table 1](#tbl1){ref-type="table"}.

Expression of EMT-related proteins in EHCC
------------------------------------------

[Figure 1A--C](#fig1){ref-type="fig"} show representative immunohistochemical staining patterns from different cases for EMT-related proteins in the areas of carcinomas and non-neoplastic epithelia of the bile ducts. E-cadherin and N-cadherin showed a membranous staining pattern ([Figure 1A and B](#fig1){ref-type="fig"}). On the other hand, CK19, vimentin, *α*-SMA and fibronectin were detected in the cytoplasm ([Figure 1A and B](#fig1){ref-type="fig"}). Although S100A4 showed cytoplasmic and nuclear staining in cancer cells, nuclear S100A4 staining was considered to be positive because of its cytoplasmic expression in the non-neoplastic component that was induced by an epithelial reaction to damage ([@bib8]; [Figure 1B](#fig1){ref-type="fig"}). Immunohistochemical localisation of EMT transcription factors was consistent with cell block analysis ([Figure 1C](#fig1){ref-type="fig"}).

Survival analysis on the basis of EMT-related protein expression
----------------------------------------------------------------

Overall patient survival rates were determined using the log-rank test with respect to expression of the 12 EMT-related proteins. In terms of epithelial markers, low expression of E-cadherin (*P*=0.0180) was correlated with a poor outcome. High expression of vimentin (*P*=0.0193), N-cadherin (*P*=0.0004), S100A4 (*P*=0.0017) and fibronectin (*P*=0.0092) was each correlated with an unfavourable prognosis. However, no significant difference in patient outcome was found with respect to the expression status of the transcription factors, CK19 and *α*-SMA ([Figure 2](#fig2){ref-type="fig"}). In addition to EMT-related proteins, univariate analysis of overall survival using the log-rank test identified venous invasion (*P*=0.0020), histological classification (*P*=0.0291), T classification (*P*=0.0357), N classification (*P*=0.0010) and residual tumour (*P*=0.0471) as significant prognostic indicators. Moreover, multivariate analysis using the Cox regression model on the same set of patients was performed using the factors shown to be significant by univariate analysis. Those results showed that low expression of E-cadherin (hazard ratio (HR), 2.09; *P*=0.0208), high expression of N-cadherin (HR, 2.53; *P*=0.0038) and high expression of S100A4 (HR, 2.51; *P*=0.0157) was each an independent unfavourable prognostic factor, in addition to N classification (HR, 1.60; *P*=0.0420; [Table 2](#tbl2){ref-type="table"}).

Relationships between patient survival and expression of E-cadherin and N-cadherin
----------------------------------------------------------------------------------

We divided the 117 cases of EHCC into the following three subgroups: A, E-cadherin high expression and N-cadherin low expression phenotype (Ecad-H/Ncad-L); B, incomplete phenotype (Ecad-H/Ncad-H or Ecad-L/Ncad-L); and C, E-cadherin low expression and N-cadherin high expression phenotype (Ecad-L/Ncad-H). In this study, we defined subgroup C as the 'cadherin switch\' phenotype because this subgroup consistently showed downregulation of E-cadherin and upregulation of N-cadherin ([@bib11]; [@bib40]; [@bib16]; [@bib2]). We showed the representative double immunohistochemical staining patterns for the cadherin switch in [Figure 3A](#fig3){ref-type="fig"}. In the immunohistochemical staining of the cell proliferation marker, Ki67, there was no significant differences of Ki67 labelling index between the cadherin switch-positive and -negative cases both in invasive front (*P*=0.9758) and bulk of tumour (*P*=0.6366; see [Supplementary Data 2](#sup1){ref-type="supplementary-material"}). In addition, to study whether the tumour reactive stroma was more expressed in specimens showing the cadherin switch, we immunohistochemically examined the expression of *α*-SMA and podoplanin, which have been reported to be the CAFs markers ([@bib3]; [@bib38]; [@bib23]; [@bib22]; [@bib13]; [@bib29]), both in invasive front and bulk of tumour. As a result, no significant correlation was found between the presence of *α*-SMA/podoplanin-expressing CAFs and the expression of cadherin switch both in invasive front and bulk of tumour (see [Supplementary Data 3](#sup1){ref-type="supplementary-material"}).

With regard to survival analysis, as shown in [Figure 3B](#fig3){ref-type="fig"}, the cadherin switch-positive group (subgroup C) was prognostically more unfavourable than the cadherin switch-negative group (subgroups A and B; *P*\<.0001, *P*=0.0099, respectively). We then performed multivariate analysis to confirm the cadherin switch as an independent prognostic factor, and included the same set of significant factors derived from univariate analysis (excluding E-cadherin and N-cadherin). This analysis showed that the cadherin switch was an independent unfavourable prognostic factor (HR, 2.34; *P*=0.0143), in addition to S100A4 expression (HR, 2.29; *P*=0.0263) and N classification (HR, 1.65; *P*=0.0316; [Table 3](#tbl3){ref-type="table"}).

Discussion
==========

Previous reports have analysed the relationship between expression of EMT-related proteins including cadherin switch and prognosis in EHCC ([@bib26]; [@bib2]; [@bib8]). However, those studies examined only a limited number of EMT-related proteins and small sample cohorts. To our knowledge, this is the first study to have investigated the correlation between the expression of multiple EMT-related proteins including representative transcription factors and clinicopathological outcomes in a large series of patients with EHCC. We confirmed that the results of immunohistochemistry performed on tissue microarrays paralleled those of the corresponding whole sections, based on the random selection of 10 cases. Among the 10 cases studied in whole sections, the staining localisation in tumour cells of each case was identical with the cores included in TMA, and the staining intensity was similar between invasive front and bulk of the tumours. According to the previous report ([@bib17]), overexpression of Zeb2, one of the EMT-related transcriptional factors, in the invasive front correlated with patients\' prognosis in colorectal cancer. On the other hand, in our pilot study, the expression of any transcriptional factor markers in the invasive front or bulk of tumour was not correlated with EHCC patients\' prognosis. Therefore, we evaluated the staining results of TMA core based on the mean value of two tumour cores (both invasive front and bulk of tumour) in each case.

We evaluated the prognostic significance of both E-cadherin and N-cadherin expression in EHCC patients as similar to that in many other carcinomas previously reported ([@bib11]; [@bib18]). In several types of carcinoma, the E- to N-cadherin switch that influences cell phenotype and behaviour as a major aspect of EMT, has found to be associated with patient prognosis ([@bib11]; [@bib40]; [@bib16]; [@bib2]). In EHCC, [@bib2] confirmed that the cadherin switch occurred in CC cells as a result of TGF-*β*-induced EMT *in vitro*, and that this cadherin switch was related to the migratory and invasive properties of CC cells. In an immunohistochemical study of 38 EHCC specimens, they also revealed that the cadherin switch was correlated with patients\' survival ([@bib2]). In this study, we demonstrated for the first time in the EHCC patients that the cadherin switch was a more significant factor associated with poor prognosis than either E-cadherin or N-cadherin alone. Multivariate analysis also showed that the cadherin switch was an independent prognostic factor. The reason why the cadherin switch is a more significant factor than altered expression of E-cadherin or N-cadherin alone is not clear. In our study, no significant difference in Ki67 labelling index was found between cadherin switch-positive and -negative groups.

Recently, it has been reported that interaction between cancer cells and surrounding CAFs has a pivotal role in cancer progression ([@bib3]; [@bib38]; [@bib23]; [@bib22]; [@bib13]; [@bib29]). One of the most common CAFs\' markers is *α*-SMA ([@bib3]; [@bib38]; [@bib13]). Detection of *α*-SMA in tumour stroma has been studied in various carcinomas, and was proposed to have an association with an aggressive phenotype of cancer cells ([@bib3]; [@bib38]; [@bib13]). Podoplanin, which is a representative lymphatic vessel marker (D2-40), have gained attention as a CAFs\' marker, and the podoplanin-expressing CAFs has been reported to be associated with malignant potential in several types of cancer ([@bib23]; [@bib22]; [@bib29]). However, in this study, no significant correlation was found between the presence of *α*-SMA/podoplanin-expressing CAFs and the expression of cadherin switch both in invasive front and bulk of tumour. Although, in some reports, the contribution of the CAFs to the cancer progression has been found ([@bib3]; [@bib38]; [@bib23]; [@bib22]; [@bib13]; [@bib29]), the exact role of CAFs in cancer is not fully understood and may have functional heterogeneity according to the types of cancer ([@bib29]). The malignant potential of the cadherin switch may be explained by the association between cadherins and the growth factor receptor signalling pathway ([@bib40]). Growth factor receptors, such as the epidermal growth factor receptor and fibroblast growth factor receptor, regulate many aspects of tumour cell behaviour, including cell motility and invasion ([@bib40]). It has been suggested that when epithelial tumour cells switch from E- to N-cadherin expression, they also gain the ability to activate growth factor receptor pathways to enhance cell growth and invasion ([@bib40]). As for cadherin switch, it is also interesting to examine the correlation between the expression of more advanced mesenchymal markers showing complete EMT, such as *α*-SMA and fibronectin, and the cadherin switch *in vitro* study. Further insight into this aspect awaits future studies.

S100A4 is a member of the S100 family of Ca^2+^-binding proteins and is expressed in both mesenchymal cells and some malignant epithelial tumours ([@bib12]; [@bib27]; [@bib8]). S100A4 is involved in the regulation of a wide range of biological phenomena including cell motility, survival, differentiation, contractility, fibrosis and EMT ([@bib27]; [@bib8]). Moreover, S100A4 has been shown to be a candidate molecular marker of metastatic potential with high prognostic significance in several cancers ([@bib12]; [@bib27]; [@bib8]). [@bib8] reported that the expression of nuclear S100A4 was an independent predictor of survival in CC including both intrahepatic (*n*=55) and extrahepatic (*n*=31) types. They also demonstrated that the nuclear expression of S100A4 was associated with the enhanced metastatic potential of CC cell lines xenotransplanted into SCID mice, and that the silencing of S100A4 was associated with reduced motility, invasiveness and the expression of MMP9 *in vitro* ([@bib8]). In our large-scale study of EHCC, S100A4 was revealed to be an independent prognostic factor, being consistent with the previous study ([@bib8]).

Transcription factors that orchestrate EMT have been correlated with poor prognosis in several types of carcinoma. For example, in the gastrointestinal tract, expression of Snail, Slug, Twist, Zeb1 and Zeb2 has been associated with unfavourable survival outcomes in patients with oesophageal ([@bib35]), gastric ([@bib18]; [@bib24]; [@bib4]), colorectal ([@bib28]; [@bib17]) or pancreatic cancer ([@bib19]). [@bib26] reported that EHCC patients whose tumours showed marked immunohistochemical expression of Snail had a significantly poorer prognosis than those with tumours showing negative or mild-to-moderate expression. Although a large number of studies have suggested that these transcription factors may be useful as prognostic parameters, our present results indicated that none of the transcription factors investigated here were predictive of patient outcome. In addition to the pathways triggered by the transcription factors investigated in this study, many other molecules, such as Kruppel-like factor 8, Goosecoid and FoxC2, have recently been described as EMT inducers ([@bib39]; [@bib33]). In EHCC, these other transcription factors may be key transcription factors inducing EMT. Moreover, a discrepancy between our results and those obtained by others may be also explained by the differences of case numbers, patients\' characteristics, antibodies used in those studies, periods of follow-up, storage conditions and the methods of fixation for the specimens. In addition, the way of setting the cutoff point for immunohistochemistry may also be a cause of inconsistency.

In conclusion, we have demonstrated that the expression of E-cadherin, N-cadherin and S100A4 may each be a novel prognostic indicator reflecting the aggressiveness of EHCC. Furthermore, the cadherin switch may be a prognostic parameter for EHCC patients, showing a higher discriminative power than expression of E-cadherin or N-cadherin alone. Although the validation of these results with the same cutoffs in an independent patient cohort is necessary, these results may provide useful information for selecting the appropriate adjuvant therapy protocol and strict surveillance for EHCC patients.
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![**Representative immunohistochemical staining patterns for 12 EMT-related markers are shown for carcinoma lesions (Ca) and non-neoplastic epithelium (N) of the bile duct.** For each marker, positive and negative areas are from different patients. (**A**) epithelial markers, (**B**) mesenchymal markers and (**C**) transcription factor markers.](bjc2014415f1){#fig1}

![**Kaplan--Meier survival curves with the log-rank test for expression of 12 EMT-related proteins.** Abbreviations: H=high expression group; L=low expression group.](bjc2014415f2){#fig2}

![**The 117 cases of EHCC are divided into three subgroups: A, E-cadherin high expression and N-cadherin low expression phenotype (Ecad-H/Ncad-L); B, incomplete phenotype (Ecad-H/Ncad-H or Ecad-L/Ncad-L); C, E-cadherin low expression and N-cadherin high expression phenotype (Ecad-L/Ncad-H).** The subgroup C is defined as the 'cadherin switch\'. (**A**) Representative double immunohistochemical staining patterns for the cadherin switch. The expression of E-cadherin; red colour, the expression of N-cadherin; brown colour. (**B**) Kaplan--Meier survival curves with the log-rank test for combined E-cadherin and N-cadherin expression. The cadherin switch-positive group (subgroup C) was prognostically more unfavourable than the cadherin switch-negative group (subgroups A and B) (*P*\<.0001, *P*=0.0099, respectively).](bjc2014415f3){#fig3}

###### Antibodies used for immunohistochemistry

  **Marker**     **Type**  **Source**                              **Clone**       **Dilution**  **Antigen retrieval**   **Immunohistochemical patterns**    **Antibody validation control cell line (positive/negative)**  **Cutoff value of immunohistochemistry (%)**
  ------------- ---------- --------------------------------------- -------------- -------------- ----------------------- ---------------------------------- --------------------------------------------------------------- ----------------------------------------------
  E-cadherin        EM     Invitrogen (Carlsbad, CA, USA)          4A2C7               RTU       Tris-EDTA               Cytoplasmic membrane                                             ---                               43
  CK19              EM     Novocastra (Newcastle-upon-Tyne, UK)    b170              1 : 100     Tris-EDTA               Cytoplasm                                                        ---                               20
  Vimentin          MM     Ventana (Basel, Switzerland)            V9                  RTU       Tris-EDTA               Cytoplasm                                                        ---                               43
  N-cadherin        MM     Dako (Carpinteria, CA, USA)             6G11               1 : 50     Tris-EDTA               Cytoplasmic membrane                                             ---                               35
  S100A4            MM     Abcam (Cambridge, UK )                  PAb (rabbit)      1 : 200     Prot K                  Nuclear                                                          ---                               50
  *α*-SMA        MM/CAFs   Dako                                    1A4                1 : 50     Tris-EDTA               Cytoplasm                                                        ---                               5[a](#t1-fn1){ref-type="fn"}
  Fibronectin       MM     Dako                                    PAb (rabbit)      1 : 2000    Prot K                  Cytoplasm                                                        ---                               8
  Snail             TF     Abcam                                   PAb (goat)        1 : 500     Tris-EDTA               Nuclear                                                      Panc1/H1299                           60
  Slug              TF     Abcam                                   PAb (rabbit)      1 : 100     Tris-EDTA               Nuclear                                                    MDA-MB231/T47D                          33
  Twist             TF     Abcam                                   Twist2C1a          1 : 20     Tris-EDTA               Nuclear                                                      T47D/Panc1                            15
  Zeb1              TF     GenWay (San Diego, CA, USA)             416A7H10           1 : 20     Tris-EDTA               Nuclear                                                    MDA-MB231/MCF7                          50
  Zeb2              TF     Novus Biological (Littleton, CO, USA)   PAb (rabbit)      1 : 400     Tris-EDTA               Cytoplasm                                                    H1299/MCF7                            63
  Podoplanin       CAFs    Dako                                    D2-40               RTU       Tris-EDTA               Stromal fibroblasts                                              ---                               30
  Ki67             ---     Dako                                    MIB-1             1 : 200     Tris-EDTA               Nuclear                                                          ---                               ---

Abbreviations: CAFs=cancer-associated fibroblasts marker; CK=cytokeratin; EM=epithelial marker; MM=mesenchymal marker; PAb=polyclonal antibody; Prot K=proteinase K solution; RTU=ready to use; *α*-SMA=*α*-smooth muscle actin; TF=transcription factor marker; Tris-EDTA=Tris-EDTA-based solution.

This cutoff value of *α*-SMA is that for the mesenchymal marker (i.e., EMT-related marker). As for the immunohistochemical evaluation of *α*-SMA as a CAFs marker, refer to the main text.

###### Survival analysis

                                               **Survival (%)**   **Univariate**   **Multivariate**                        
  -------------------------------------- ----- ------------------ ---------------- ------------------- ------------------- -------------------
  **Gender**                                                                                                               
  Male                                   92    41.7               32.1             0.4798                                   
  Female                                 25    36.0               24.0                                                      
  **Age**                                                                                                                  
  \<71                                   56    40.0               29.1             0.4722                                   
  ⩾71                                    61    40.9               33.5                                                      
  **Tumour size**                                                                                                          
  \<3 cm                                 89    41.5               31.6             0.2027                                   
  ⩾3 cm                                  28    37.2               26.0                                                      
  **Location**                                                                                                             
  Distal                                 43    33.3               30.7             0.4266                                   
  Perihilar                              74    44.5               30.0                                                      
  **Macroscopic type**                                                                                                     
  Papillary                              18    50.0               37.5             0.5582                                   
  Non-papillary                          99    38.7               29.0                                                      
  **Depth of tumour invasion**                                                                                             
  Within fm                              8     75.0               37.5             0.1633                                   
  Beyond fm                              109   37.9               29.9                                                      
  **Invasion to the hepatic artery**                                                                                       
  Negative                               112   40.5               30.8             0.9620                                   
  Positive                               5     40.0               20.0                                                      
  **Invasion to the portal vein**                                                                                          
  Negative                               91    43.3               35.0             0.1554                                   
  Positive                               26    30.7               15.3                                                      
  **Lymphatic vessel invasion**                                                                                            
  Negative                               40    55.0               39.1             0.1322                                   
  Positive                               77    32.9               25.4                                                      
  **Venous invasion**                                                                                                      
  Negative                               52    57.6               45.4             **[0.0020]{.ul}**   1.00                0.2002
  Positive                               65    26.5               18.2                                 1.37 (0.85--2.22)    
  **Perineural invasion**                                                                                                  
  Negative                               15    46.6               33.3             0.5534                                   
  Positive                               102   39.6               29.9                                                      
  **Superficial spread**                                                                                                   
  Negative                               97    40.6               29.8             0.9510                                   
  Positive                               20    40.0               33.3                                                      
  **Histopathological classification**                                                                                     
  Well+Pap                               37    59.4               45.1             **[0.0291]{.ul}**   1.00                0.3528
  Mod+poor+others                        80    31.6               23.5                                 1.29 (0.75--2.26)    
  **pT**                                                                                                                   
  1+2                                    62    48.3               39.8             **[0.0357]{.ul}**   1.00                0.4162
  3+4                                    55    31.5               19.8                                 1.22 (0.76--1.96)    
  **pN**                                                                                                                   
  0                                      63    52.3               42.4             **[0.0010]{.ul}**   1.00                **[0.0420]{.ul}**
  1                                      54    26.4               16.0                                 1.60 (1.02--2.54)    
  **pStage**                                                                                                               
  I+II                                   66    47.6               39.4             0.0607                                   
  III+IV                                 51    31.3               19.0                                                      
  **R**                                                                                                                    
  0                                      95    44.7               33.5             **[0.0471]{.ul}**   1.00                0.4475
  1                                      22    22.7               17.1                                 1.27 (0.67--2.29)    
  **E-cadherin**                                                                                                           
  High expression                        21    61.9               56.7             **[0.0180]{.ul}**   1.00                **[0.0208]{.ul}**
  Low expression                         96    35.8               24.4                                 2.09 (1.11--4.27)    
  **Vimentin**                                                                                                             
  Low expression                         101   44.0               32.3             **[0.0193]{.ul}**   1.00                0.5662
  High expression                        16    18.7               18.7                                 1.21 (0.61--2.25)    
  **N-cadherin**                                                                                                           
  Low expression                         95    46.8               34.2             **[0.0004]{.ul}**   1.00                **[0.0038]{.ul}**
  High expression                        22    13.6               13.6                                 2.53 (1.36--4.54)    
  **S100A4**                                                                                                               
  Low expression                         104   44.2               32.8             **[0.0017]{.ul}**   1.00                **[0.0157]{.ul}**
  High expression                        13    8.3                8.3                                  2.51 (1.20--4.96)    
  **Fibronectin**                                                                                                          
  Low expression                         76    48.0               36.2             **[0.0092]{.ul}**   1.00                0.9093
  High expression                        41    26.8               19.5                                 1.08 (0.64--1.79)    

Abbreviation: CI=confidence interval. The bold and underlined entities indicate statistical significance (*P*\<0.05).

###### Multivariate analysis including the cadherin switch

  **Characteristics**                                         **HR**    **95% CI of relative risk**  ***P*****-value**
  ----------------------------------------------------------- -------- ----------------------------- -------------------
  Venous invasion (negative vs positive)                      1.54              0.97--2.50           0.0681
  Histological classification (well+Pap vs mod+poor+others)   1.14              0.67--1.98           0.6218
  T classification (1+2 vs T3+4)                              1.28              0.80--2.03           0.3024
  N classification (negative vs positive)                     1.65              1.05--2.62           **[0.0316]{.ul}**
  Residual tumour (R0 vs R1/R2)                               1.21              0.65--2.16           0.5348
  Vimentin (low vs high expression)                           1.34              0.68--2.47           0.3819
  S100A4 (low vs high expression)                             2.29              1.11--4.45           **[0.0263]{.ul}**
  Fibronectin (low vs high expression)                        1.06              0.64--1.74           0.8194
  Cadherin switch (negative vs positive)                      2.34              1.19--4.35           **[0.0143]{.ul}**

Abbreviations: CI=confidence interval; HR=hazard ratio. The bold and underlined entities indicate statistical significance (*P*\<0.05).
